Uterine fibroid

Revere Securities acted as exclusive Placement Agent on a private placement of $1.6 million of Senior Secured Convertible Notes for Embolx, Inc.

Retrieved on: 
Monday, October 31, 2022
Pressure, LLC, Compliance, Family, Sale, Industry, Company, Immunotherapy, Tissue, Private, Senior, Neoplasm, Uterine fibroid, Silicon, Sniper

The proceeds of the offering will be utilized to fund the further commercialization of the Company's products.

Key Points: 
  • The proceeds of the offering will be utilized to fund the further commercialization of the Company's products.
  • Revere Securities is a global broker-dealer firm providing strategic and financial support to institutional investors, hedge funds, and individual investors.
  • In addition, Revere Securities LLC provides differentiated corporate access, helping institutional clients gain access to management as a component of their investment process.
  • The firm has industry focused sales specialists who possess "buy-side" experience; therefore, providing a sound, alternate perspective, to the investment process.

Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide

Retrieved on: 
Wednesday, October 26, 2022
Congress, Leuprorelin, Therapy, Woman, Society, Biotechnology, IV, Research, Man, Nasdaq, Reproductive medicine, III, CDMO, Area studies, Pharmacokinetics, Practice management, Safety, Prostate cancer, Injection, Genetics, Gonadotropin-releasing hormone, Infertility, Uterine fibroid, American Society for Reproductive Medicine, Peptide, ASRM, BCS, Endometriosis, Pharmaceutical industry, Birth control

BOONTON, N.J., Oct. 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that research into the pharmacokinetics of an oral formulation of leuprolide (Ovarest®) utilizing Enteris' proprietary Peptelligence® platform was highlighted in an oral presentation at the ASRM 2022 Scientific Congress & Expo in Anaheim, Calif. 

Key Points: 
  • Enteris Chief Medical Officer Dr. Gary Shangold, who was lead author of the study titled "Pharmacokinetic (PK) Study of Oral Leuprolide Delivery with Ovarest Achieves Drug Levels Exceeding those of Approved Injectable Formulations,"gave the presentation today.
  • The research detailed the results from a 22-patient study examining the pharmacokinetic (PK) profile and dose-proportionality of oral leuprolide compared to historical data for highly effective injectable leuprolide products.
  • Results from the study confirmed that the oral delivery of leuprolide produced levels expected to be within established therapeutic ranges with Ovarest delivering more drug than highly effective injectable leuprolide formulations.
  • For more information on Enteris BioPharma and its proprietary oral drug delivery technologies, please visit http://www.EnterisBioPharma.com .

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
Tuesday, October 18, 2022
LinkedIn, RSU, Female, MHRA, Review, Woman, New Drug Application, Employment, NYSE, Twitter, Man, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medicines and Healthcare products Regulatory Agency, Pain, Safety, USPI, GLOBE, EC, RWS, Infertility, Uterine fibroid, FDA, Pregnancy, Endometriosis, Pharmaceutical industry

The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.

Key Points: 
  • The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
  • The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 96,500 common shares ofMyovant.
  • The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.

Campaign for Safe Cosmetics Publishes First-Ever List of Top Non-Toxic Black-Owned Beauty Brands & Product Database

Retrieved on: 
Tuesday, October 18, 2022
SAN, Movement, Disease, Risk, Woman, Maternal health, Organization, Beauty Brands, Campaign for Safe Cosmetics, Health equity, Program, Advisory Committee, CSC, Mortality, Breast cancer, Cancer, Awareness, Hair, Health, Campaign, Ectopic pregnancy, Breast, Safety, Diabetes, Endometriosis, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, GLOBE, Infertility, Uterine fibroid, Database, Beauty, Lead, Breast Cancer Awareness Month, Cosmetics, Birth control, Cosmetics, Black

This project brings health equity to the forefront by providing a database of clean beauty products to help Black women and girls live their healthiest lives and prevent breast cancer.

Key Points: 
  • This project brings health equity to the forefront by providing a database of clean beauty products to help Black women and girls live their healthiest lives and prevent breast cancer.
  • CSC's Top Non-Toxic Black Beauty Brands 2022 > CSC'sNon-Toxic Black Beauty Product Database >
    Released during Breast Cancer Awareness Month, the Non-Toxic Black Beauty Project focuses specifically on supporting Black women's health because Black women face the highest breast cancer mortality rate of any racial or ethnic group in America.
  • Beauty products marketed to Black women often contain the most toxic cosmetics ingredients, including chemicals linked to cancer.
  • "We are thrilled to announce the launch of our searchable database of non-toxic Black beauty products," said Janet Nudelman, Director of the Campaign for Safe Cosmetics, a program of Breast Cancer Prevention Partners.

Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.

Retrieved on: 
Friday, October 14, 2022
LinkedIn, Medicines and Healthcare products Regulatory Agency, Female, Webcast, MHRA, Royal commission, Woman, Review, New Drug Application, Roivant Sciences, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Twitter, Man, Food, Pain, Safety, USPI, GLOBE, EC, RWS, Infertility, Uterine fibroid, FDA, Pregnancy, Endometriosis, European Commission, Pharmaceutical industry

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.

Key Points: 
  • BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.
  • The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022.
  • Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.
  • Myovant also is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis.

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

Retrieved on: 
Thursday, October 13, 2022
Investor, National Medical Products Administration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Humanitarian Device Exemption, MRI, Technology, Health Canada, Food, Company, Rectum, Hyperthermia, Urethra, Hematuria, Prostate cancer, CE, Webcast, Uterine fibroid, FDA, Bone, Pharmaceutical industry, Medical imaging

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago   

Retrieved on: 
Wednesday, October 12, 2022
Vestibular adenitis, LinkedIn, Innovation, Lipoma, Decompression, Ultrasound, Injury, Pelvis, Securities Act of 1933, Spine, Leiomyoma, NEXUS, Ovary, Inclusion, Failure, Surgeon, Cardiothoracic surgery, Evidence-based medicine, Twitter, Access, North American Spine Society, Company, Gastrointestinal tract, Orthopedic surgery, GLOBE, Uterine fibroid, Projection, Government, Growth, Review, Uterus, Research, Security (finance), NASS, Neurosurgery, Plastic and Reconstructive Surgery, Securities Exchange Act of 1934, MIS, U.S. Securities and Exchange Commission, General surgery, Sebaceous cyst, Terminology, Risk, Physician, Cedars-Sinai Medical Center, SEC, Patient, Nasdaq, Malignancy, Sex, Acquisition, Extremities, Forward-looking statement, COVID-19, Cardiac fibroma, Sebaceous gland, Bookbinding, Medical imaging, Gynaecology, MD

The BoneScalpel Access handpiece 20 mm blade and Micro Hook Shaver will be available throughout the U.S. on October 17.

Key Points: 
  • The BoneScalpel Access handpiece 20 mm blade and Micro Hook Shaver will be available throughout the U.S. on October 17.
  • The BoneScalpel Access handpiece allows surgeons to leverage the many advantages of ultrasonic bone cutting in minimally invasive spinal procedures.
  • Combined with OSTEOAMP Flowable, Bioventus now has a full portfolio for MIS spine procedures, the fastest growing segment of spine surgery.
  • The Bioventus surgical solutions portfolio brings together innovative products that add value for surgical applications in decompression and fusion.

Kindbody's Nationwide Expansion Continues with Opening of Houston Clinic

Retrieved on: 
Tuesday, October 11, 2022
National Institutes of Health, Adoption, Reproductive health, Emory University, Walter Reed National Military Medical Center, Parent, Education, Gynaecology, Patient, Restaurant, NIH, Research, Program, Corporation, GV (company), University, MedStar Georgetown University Hospital, National, Society, CEO, IVF, Genetic testing, Fertility, Howard Hughes Medical Institute, Infertility, Uterine fibroid, Heart, Obstetrics, Fertility preservation, Medicine

NEW YORK, Oct. 11, 2022 /PRNewswire/ -- Kindbody, a leading fertility clinic network and family-building benefits provider for employers offering comprehensive virtual and in-person care, today announced the opening of a state-of-the-art clinic and IVF lab in Houston, TX. Kindbody Houston was built to meet the growing demand for comprehensive fertility and family-building benefits by employers in the area, which has experienced record job growth with its thriving local economy. Open to the entire Houston community, Kindbody Houston is led by Dr. Toral Parikh, a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology. Dr. Parikh is currently accepting patients. The opening marks the company's second location in Texas which is also home to Kindbody Austin. A third Texas location will launch in Dallas later this year.

Key Points: 
  • NEW YORK, Oct. 11, 2022 /PRNewswire/ -- Kindbody , a leading fertility clinic network and family-building benefits provider for employers offering comprehensive virtual and in-person care, today announced the opening of a state-of-the-art clinic and IVF lab in Houston, TX.
  • Open to the entire Houston community, Kindbody Houston is led by Dr. Toral Parikh, a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology.
  • The opening marks the company's second location in Texas which is also home to Kindbody Austin.
  • "We're excited to bring Kindbody's mission of accessible, high-quality fertility care to Houston employers and the entire community," said Annbeth Eschbach, CEO, Corporate of Kindbody.

Runway Growth Finance Corp. Provides Third Quarter 2022 Portfolio Update

Retrieved on: 
Thursday, October 6, 2022
Health, Securities & Exchange Commission of Pakistan, Fidelis, Weight loss, Communication, IOT, Efficiency, Growth, Uterus, Software as a service, Organization, NYSE, NASDAQ, IO, Security (finance), Completion, Investment, Nasdaq, Technology, Private Securities Litigation Reform Act, Solution, Fibroid, Investment Company Act of 1940, Industry, AI, Information services, CEO, Internet, U.S. Securities and Exchange Commission, TCON, FiscalNote, GLOBE, Uterine fibroid, Hysterectomy, List, COVID-19, Air traffic control, Compliance, Renewable energy, Bank, Runway

WOODSIDE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Runway Growth) (Nasdaq: RWAY), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the third quarter ended September 30, 2022.

Key Points: 
  • WOODSIDE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Runway Growth) (Nasdaq: RWAY), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the third quarter ended September 30, 2022.
  • Fueled by prudent deployment of leverage and further expansion of our investment team, Runway Growth delivered record third quarter originations, completing nine investments in new and existing portfolio companies, said David Spreng, Founder and CEO of Runway Growth.
  • In the third quarter of 2022, Runway Growth funded nine investments: two investments in new portfolio companies, and seven new investments in existing portfolio companies.
  • In summary, Runway Growth is constructing a portfolio that provides stable yields and attractive returns from debt investments.

Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares

Retrieved on: 
Monday, October 3, 2022
Slate, Uterine fibroid, Company, GLOBE, New Drug Application, Female, Review, LinkedIn, USPI, Audit committee, Private Securities Litigation Reform Act, Man, Food, U.S. Securities and Exchange Commission, European Commission, Medicines and Healthcare products Regulatory Agency, Twitter, Form, Pain, Infertility, FDA, RWS, Risk, Canadian House of Commons Special Committee on Electoral Reform, Committee, Skadden, MHRA, Safety, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Communication, Security (finance), Endometriosis, Sumitomo Group, Goldman Sachs, Forward-looking statement, Proposal, EC, Disclosure, Pregnancy, Woman, Special, Roivant Sciences, Royal commission, Pharmaceutical industry

Sumitovant currently holds approximately 52% of the outstanding shares of the Company.

Key Points: 
  • Sumitovant currently holds approximately 52% of the outstanding shares of the Company.
  • Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.
  • Myovant also is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis.
  • Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovants majority shareholder.